First, we exhausted all available clinical trial data and authoritative MNA results to compare the lifetime healthcare cost and clinical outcomes of all first-line therapy preferentially approved by FDA, including three ICI monotherapies and one ICI combination therapy, which may add important cost-effectiveness evidence to inform the preferred treatment options for advanced NSCLC patients with PD-L1 of at least 50%. This evidence concerns the gene CD274 and non-small cell lung carcinoma.